ODM 103

Drug Profile

ODM 103

Alternative Names: ODM-103

Latest Information Update: 10 Feb 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Orion
  • Class Antiparkinsonians
  • Mechanism of Action Catechol-O-methyltransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Parkinson's disease

Most Recent Events

  • 04 Feb 2015 Discontinued - Phase-I for Parkinson's disease (In volunteers) in Germany (PO)
  • 01 Sep 2014 Orion Corporation completes a phase I trial in Parkinson's disease (In volunteers) in Germany (NCT01688089)
  • 01 Nov 2013 Orion suspends enrolment in a phase I trial in healthy volunteers in Germany (NCT01688089)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top